You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

Rhinology

On demand events

ERS-ISIAN 2023 | Optimizing Patient Outcomes in CRSwNP: Guidelines and Shared Decision-Making

Prof. Peter Hellings and Dr. Stella Lee discuss the current landscape of CRSwNP guidelines and treatment for optimizing patient outcomes.

MD, PhD

Peter Hellings +1 more

Learning objectives

Learn how type 2 inflammation underlies the pathophysiology of CRSwNP, and how this inflammation translates to the signs and symptoms most important to patients
Discuss partnering with patients to improve outcomes, and review the strengths and weaknesses of current guideline recommendations and standard of care for patients with CRSwNP
Review the comparative efficacy of biologics approved for patients with severe/uncontrolled CRSwNP, and discuss navigating the current treatment landscape in CRSwNP

About these experts

Rhinology

MD, PhD

Peter Hellings

Professor and Clinic Head of the Department of Otorhinolaryngology | University Hospitals of Leuven, Belgium

Rhinology

Stella Lee

Chief of Rhinology at Brigham and Women’s Hospital | Harvard Medical School, Boston, United States

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: GuatemalaChange country/region